Goldman Sachs Group Inc Celldex Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,835,843 shares of CLDX stock, worth $46.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,835,843
Previous 874,193 110.0%
Holding current value
$46.2 Million
Previous $32.4 Million 92.76%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$32.06 - $44.56 $30.8 Million - $42.9 Million
961,650 Added 110.0%
1,835,843 $62.4 Million
Q2 2024

Aug 13, 2024
BUY
$32.76 - $42.56 $10.1 Million - $13.2 Million
309,390 Added 54.78%
874,193 $32.4 Million
Q1 2024

May 15, 2024
BUY
$35.22 - $51.88 $4.47 Million - $6.59 Million
127,044 Added 29.02%
564,803 $23.7 Million
Q4 2023

Feb 13, 2024
BUY
$22.61 - $40.65 $586,164 - $1.05 Million
25,925 Added 6.3%
437,759 $17.4 Million
Q3 2023

May 14, 2024
SELL
$25.45 - $37.46 $659,791 - $971,150
-25,925 Reduced 5.92%
411,834 $11.3 Million
Q3 2023

Nov 14, 2023
SELL
$25.45 - $37.46 $790,629 - $1.16 Million
-31,066 Reduced 7.01%
411,834 $11.3 Million
Q2 2023

May 14, 2024
BUY
$30.29 - $38.28 $2.51 Million - $3.17 Million
82,727 Added 22.97%
442,900 $15 Million
Q2 2023

Aug 14, 2023
BUY
$30.29 - $38.28 $2.51 Million - $3.17 Million
82,727 Added 22.97%
442,900 $15 Million
Q1 2023

May 14, 2024
SELL
$34.78 - $47.43 $3.11 Million - $4.24 Million
-89,411 Reduced 19.89%
360,173 $13 Million
Q1 2023

May 11, 2023
SELL
$34.78 - $47.43 $3.11 Million - $4.24 Million
-89,411 Reduced 19.89%
360,173 $13 Million
Q4 2022

May 14, 2024
SELL
$27.78 - $45.38 $5.97 Million - $9.75 Million
-214,847 Reduced 32.34%
449,584 $20 Million
Q4 2022

Feb 13, 2023
SELL
$27.78 - $45.38 $5.97 Million - $9.75 Million
-214,847 Reduced 32.34%
449,584 $20 Million
Q3 2022

May 14, 2024
BUY
$22.7 - $37.57 $5.1 Million - $8.44 Million
224,719 Added 51.11%
664,431 $18.7 Million
Q3 2022

Nov 10, 2022
BUY
$22.7 - $37.57 $5.1 Million - $8.44 Million
224,719 Added 51.11%
664,431 $18.7 Million
Q2 2022

May 14, 2024
BUY
$20.5 - $37.33 $40,036 - $72,905
1,953 Added 0.45%
439,712 $11.9 Million
Q2 2022

Aug 15, 2022
BUY
$20.5 - $37.33 $2.79 Million - $5.09 Million
136,293 Added 44.92%
439,712 $11.9 Million
Q1 2022

May 16, 2022
BUY
$27.64 - $39.32 $1.36 Million - $1.93 Million
49,205 Added 19.36%
303,419 $10.3 Million
Q4 2021

Feb 14, 2022
SELL
$35.68 - $56.27 $1.91 Million - $3.01 Million
-53,465 Reduced 17.38%
254,214 $9.82 Million
Q3 2021

Nov 10, 2021
BUY
$28.95 - $55.99 $8.91 Million - $17.2 Million
307,679 New
307,679 $16.6 Million

Others Institutions Holding CLDX

# of Institutions
207
Shares Held
67.3M
Call Options Held
1.69M
Put Options Held
980K
View Full List

About Celldex Therapeutics, Inc.

CLDX Quotes by TradingView
  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.18B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email